middle-of-the-night awakening

(redirected from nocturnal awakening)

middle-of-the-night awakening

Insomnia characterised by a difficulty in returning to sleep once awakened after going to sleep for the night and before getting up at one’s usual time in the morning. MOTN awakening is associated with excessive daytime sleepiness and fatigue.

Frequency
Occurs in one-third of the general population at least three nights/week.

Aetiology
Anxiety, obstructive sleep apnoea, chronic pain, pregnancy, toilet needs, depression, bipolar disorder, obesity, hypertension, heart disease, alcohol consumption, menopause, etc.

Management
No medication is consistently effective.
Mentioned in ?
References in periodicals archive ?
When this disturbance occurs at night, when cortisol levels should be at their lowest, the quality of insomnia is typically an alert "ready to get to work" one, or agitated and hypervigilant, or even a startled or shocked sensation on sudden nocturnal awakening.
Also, at 8 months the infants in the experimental group were less likely to snore, needed less feeding upon nocturnal awakening and were reported to have been more alert during the day.
In addition, frequent nocturnal awakening can also lead to behavioral problems as a result of daytime sleepiness, and can accentuate developmental delays.
Some study data have suggested certain subgroups, such as patients with episodes of nocturnal awakening and those with a body mass index greater than 30 kg/[m.
Some studies have suggested that certain subgroups, such as patients with episodes of nocturnal awakening and those with a body mass index greater than 30 kg/[m.
If approved, Silenor([R]) is expected to be the first and only non-controlled prescription sleep medication in Canada indicated for the treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakening and/or early morning awakenings.
Similarly, about half of our patients reported insomnia, nocturnal awakenings, and early morning awakenings, and nearly all (90%) reported fatigue.
The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
They found agitated sleep with frequent periods of nocturnal awakenings, and a decrease of the duration and percentage of the deeper rapid eye movement (REM) sleep--also found in other forms of insomnia caused by magnesium deficiency.
Also, eplivanserin at 5 mg/day resulted in a 64% reduction in the number of nocturnal awakenings, compared with a 36% decrease with placebo.
Acthar Gel (repository corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with multiple sclerosis and Doral[R] (quazepam), that is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Also they found an increased number of nocturnal awakenings and decreased total sleep time related to smaller amounts of non-REM sleep.